Cierra raises $21m for catheter-based heart-treatment to reduce migraine:
This article was originally published in Clinica
Executive Summary
Cierra, which is developing a catheter system to treat the heart defect, patent foramen ovale (PFO), has raised $21m from venture investors led by Delphi Ventures. A PFO is a valve-like opening between the left and right atria, which studies have linked to migraine headaches. The Redwood, California company will use the funds to begin US clinical trials and commercialise its PFX non-implant-based system to close the hole with a view to reducing migraine in sufferers. Other companies offering implant-based closure of PFO include NMT Medical (Boston, Massachusetts) and AGA Medical (Golden Valley, Minnesota).
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.